Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel

Anti-Cancer Drugs

Volumn 15, Issue 10, 2004, Pages 947-954

  Blanc, Emmanuelle ^a   Bonnafous, Cécile ^a   Merida, Peggy ^a   Cisternino, Salvatore ^b   Clair, Philippe ^c   Scherrmann, Jean Michel ^b   Temsamani, Jamal ^c  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b HÔPITAL FERNAND WIDAL   (France)

^c Synt:em   (France)

Author keywords

Brain uptake; Multidrug resistance; P glycoprotein; Paclitaxel; Peptide conjugate; SynB vector

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELL CYCLE; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; MICE; OLIGOPEPTIDES; P-GLYCOPROTEIN; PACLITAXEL; RATS; SOLUBILITY; SUCCINIC ACID;

EID: 9344254931     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200411000-00003     Document Type: Article

References (46)

1. Huizing MT, Misser VH, Pieters RC, Ten Bokkel Huinink WW, Veenhof CH, Vermerken JB, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13:381-404.
2. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, Donehower RC. Taxol: pharmacology, metabolism and clinical implications. Cancer Surv 1993; 17:283-301.
3. Parness J, Horwitz SB. Taxol binds to polymerised tubulin in vitro. J Cell Biol 1981; 91:479-487.
4. Manfreddi JJ, Parness J, Howitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982; 94:688-696.
5. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90:9552-9556.
6. Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubules dynamics. Biochemistry 1995; 34:2203-2211.
7. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-1268.
8. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.
9. Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, et al. Overview of Taxol safety. J Natl Cancer Inst Monogr 1993; 15:131-139.
10. Cabral F, Barlow SB. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubules assembly. FASEB J 1989; 3:1593-1599.
11. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, et al. Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 1994; 85:290-297.
12. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-17125.
13. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427.
14. Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994; 13:223-233.
15. Jachez B, Nordamin R, Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptide SDZ. J Natl Cancer Inst 1993; 85:478-483.
16. Cardarelli CO, Aksentijerich I, Pastan I, Gottesman MM. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 1995; 55:1086-1091.
17. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56:4171-4179.
18. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002; 110:1309-1318.
19. GaIIo JM, Li S, Quo P, Reed K, Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 2003; 63:5114-5117.
20. Lee JS, Pisters KM, Komaki R, Glisson BS, Khuri FR, Schea R, et al. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. Semin Oncol 1997; 24(4 suppl 12):S52-S55.
21. Glantz MJ, Chamberlain MC, Chang SM, Prados MD, Cole BF. The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol 1999; 9:27-33.
22. Brandes AA, Pasetto LM, Monfardini S. New drugs in recurrent high grade gliomas. Anticancer Res 2000; 20:1913-1920.
23. Blasberg RG, Groothuis DR. Chemotherapy of brain tumors: physiological and pharmacokinetics considerations. Semin Oncol 1986; 13: 70-82.
24. Abbott NJ, Romero IS. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996; 2:106-113.
25. Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 1994; 34:465-471.
26. Heimans JJ, Vermerken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, et al. Paclitaxel (taxol) concentrations in brain tumor tissue. Ann Oncol 1994; 5:951-953.
27. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86:695-698.
28. Beaulieu E, Demure M, Whites L, Believe R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997; 326:539-544.
29. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression, transport activity and up-regulation of the multidrug-resistance Abcg2/Bcrp1 at the mice blood-brain barrier. Cancer Res 2004; 64:3296-3301.
30. Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neuro-Oncol 1994; 20: 121-139.
31. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000; 57:679-686.
32. Rousselle C, Smirnova M, Clair P, Lefauconnier JM, Chavanieu A, Calas B, et al. Enhanced delivery of doxorubicin into brain via a peptide-vector mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 2001; 296:124-131
33. Rousselle C, Clair P, Temsamani J, Scherrmann JM. Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy. J Drug Target 2002; 10:309-315.
34. Rousselle C, Clair P, Smirnova M, Kolesnikov Y, Pasternak GW, Gac-Breton S, et al. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J Pharmacol Exp Ther 2003; 306: 371-376.
35. Mazel M, Clair P, Rousselle C, Vidal P, Scherrmann JM, Mathieu D, et al. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs 2001; 12:107-116.
36. Atherton E, Sheppard RC. Reaction procedures and operating techniques. In: Rockwood D, Hams BD (editors): Solid Phase Peptide Synthesis: A Practical Approach. Oxford: IRL Press; 1989, pp. 131-137.
37. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 2000; 20:381-386.
38. Smith QR. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm Biotechnol 1996; 8: 285-307.
39. Ghose AK, Grippen GM. Atomic physicochemical parameters for three-dimensional structure directed quantitative structure-activity relationships I. partition coefficients as a measure of hydrophobicity. J Comput Chem 1986; 7:565-577.
40. Rice A, Michaelis ML, Georg G, Liu Y, Turunen B, Audus KL. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J Mol Neurosci 2003; 20:339-343.
41. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, Van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 2003; 53:173-178.
42. Nagy Z, Peters H, Huttner I. Charge-related alterations of the cerebral endothelium. Lab Invest 1983; 49:662-671.
43. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Ohem 2003; 278:31192-31201.
44. Terasaki T, Takakuwa S, Saheki A, Moritani S, Shimura T, Tabata S, Tsuji A. Adsorptive-mediated endocytosis of an adrenocorticotropic hormone (ACTH) analogu, ebiratide, into the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells. Pharm Res 1992; 9:529-534.
45. Mellado W. Preparation and biological activity of Taxol acetates. Biochem Biophys Res Commun 1984; 124:329-336.
46. Kingston DG. Taxol: the chemistry and structure-activity relationships of a novel anticancer agent. Trends Biotechnol 1994; 12:222-227.